DK2934479T3 - Ciclesonid til behandling af luftvejssygdomme hos heste - Google Patents
Ciclesonid til behandling af luftvejssygdomme hos heste Download PDFInfo
- Publication number
- DK2934479T3 DK2934479T3 DK13811924.3T DK13811924T DK2934479T3 DK 2934479 T3 DK2934479 T3 DK 2934479T3 DK 13811924 T DK13811924 T DK 13811924T DK 2934479 T3 DK2934479 T3 DK 2934479T3
- Authority
- DK
- Denmark
- Prior art keywords
- ciclesonide
- pharmaceutically acceptable
- acceptable salt
- composition
- inhaler
- Prior art date
Links
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 title claims description 270
- 229960003728 ciclesonide Drugs 0.000 title claims description 265
- 241000283086 Equidae Species 0.000 title claims description 100
- 208000023504 respiratory system disease Diseases 0.000 title claims description 46
- 238000011282 treatment Methods 0.000 title description 92
- 150000003839 salts Chemical class 0.000 claims description 129
- 241000283073 Equus caballus Species 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 87
- 229960000257 tiotropium bromide Drugs 0.000 claims description 60
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 51
- 239000012669 liquid formulation Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000000884 Airway Obstruction Diseases 0.000 claims description 12
- 230000000306 recurrent effect Effects 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 10
- 208000019693 Lung disease Diseases 0.000 claims description 9
- 208000011623 Obstructive Lung disease Diseases 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- -1 HFA 227 and HFA 134a Chemical class 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 10
- 238000001994 activation Methods 0.000 claims 3
- 210000000003 hoof Anatomy 0.000 claims 1
- 238000009304 pastoral farming Methods 0.000 claims 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 56
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 50
- 229960003957 dexamethasone Drugs 0.000 description 49
- 229960000890 hydrocortisone Drugs 0.000 description 28
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 24
- 229960004436 budesonide Drugs 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000000651 prodrug Substances 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 16
- 230000004199 lung function Effects 0.000 description 15
- 230000009467 reduction Effects 0.000 description 13
- 230000002123 temporal effect Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000003862 glucocorticoid Substances 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 230000000241 respiratory effect Effects 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 229960002714 fluticasone Drugs 0.000 description 9
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 210000000440 neutrophil Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010025327 Lymphopenia Diseases 0.000 description 7
- 206010029379 Neutrophilia Diseases 0.000 description 7
- 231100001023 lymphopenia Toxicity 0.000 description 7
- 108700025647 major vault Proteins 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229940041682 inhalant solution Drugs 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- 229940037128 systemic glucocorticoids Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 3
- 229960000289 fluticasone propionate Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- OXPLANUPKBHPMS-ZXBNPROVSA-N desisobutyrylciclesonide Chemical compound C1([C@@H]2O[C@@H]3C[C@H]4[C@H]5[C@@H]([C@]6(C=CC(=O)C=C6CC5)C)[C@@H](O)C[C@@]4([C@@]3(O2)C(=O)CO)C)CCCCC1 OXPLANUPKBHPMS-ZXBNPROVSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229940071648 metered dose inhaler Drugs 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000003918 potentiometric titration Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CDOOAUSHHFGWSA-OWOJBTEDSA-N (e)-1,3,3,3-tetrafluoroprop-1-ene Chemical compound F\C=C\C(F)(F)F CDOOAUSHHFGWSA-OWOJBTEDSA-N 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- GEDPQKGMHLHFOZ-UHFFFAOYSA-N 2,4-dibromo-6-[[(4-hydroxycyclohexyl)amino]methyl]phenol Chemical compound C1CC(O)CCC1NCC1=CC(Br)=CC(Br)=C1O GEDPQKGMHLHFOZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000122871 Caryocar villosum Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- QIEPWCSVQYUPIY-LEKSSAKUSA-N Delta(1)-progesterone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 QIEPWCSVQYUPIY-LEKSSAKUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241001670226 Equus caballus x asinus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000004868 gas analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012000 impulse oscillometry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GKLVIAQLYSDWGM-YNDBTVFMSA-N methyl (1r,3as,4s,5r,8s,9ar)-8-[(1r,3as,4r,7ar)-7a-methoxycarbonyl-1,3a,4-trimethyl-7-oxo-1,2,3,4-tetrahydroinden-5-yl]-5-hydroxy-1,3a,4-trimethyl-9-oxo-1,2,3,4,5,6,7,8-octahydrocyclopenta[b]naphthalene-9a-carboxylate Chemical compound O=C1[C@@]2(C(=O)OC)[C@H](C)CC[C@@]2(C)[C@H](C)C([C@H](O)CC2)=C1[C@@H]2C([C@H]1C)=CC(=O)[C@]2(C(=O)OC)[C@@]1(C)CC[C@H]2C GKLVIAQLYSDWGM-YNDBTVFMSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste.
2. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor luftvejssygdommen er en lungesygdom.
3. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 eller 2 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor luftvejssygdommen er udvalgt fra gruppen bestående af: tilbagevendende luftvejsobstruktion (RAO), sommergræsningsforbundet obstruktiv lungesygdom (SPAOPD) og inflammatorisk luftvejssygdom (IAD).
4. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 3 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor luftvejssygdommen er RAO.
5. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 4 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf er inhalerbar.
6. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 5 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf er i en flydende formulering, fortrinsvis omfattende en eller flere af opløsningsmidlerne vand, ethanol, en eller flere hydrofluoralkaner såsom HFA 227 og HFA 134a, en eller flere hydrofluorolefiner såsom HFO1234ze, og eventuelt yderligere excipienser.
7. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 6 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf er i flydende formulering, fortrinsvis er opløsningsmidlet i den flydende formulering dels vand og dels ethanol, mest foretrukket består opløsningsmidlet i den flydende formulering af en blanding af > 85 % vol/vol ethanol og < 15 % vol/vol vand, såsom for eksempel 10 % vol/vol vand og 90 % vol/vol ethanol.
8. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 7 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives via en (hov-dyrsjinhalatoranordning.
9. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 8 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor inhalatoranordningen omfatter: a. en tryksat inhalator med afmålte doser eller en vand/ethanol-dråbeinhalator såsom Respimat®-inhalatoren eller en anden inhalatoranordning, der gør brug af den aerosoldannende Respimat®-teknologi og b. en tilpasningsdel til hovdyrsbrug.
10. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 9 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf er en delvist ethanolba-seret formulering og indgives via en (hovdyrs)inhalatoranordning.
11. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 10 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives i en dosis på mindst 900 pg ex inhalator, mindst 1800 pg ex inhalator, mindst 2400 pg ex inhalator eller mindst 2700pg ex inhalator, fortrinsvis mindst 2700pg ex inhalator.
12. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 11 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives i en dosis på 100 pg til 5000 pg ex inhalator, 450 pg til 2700 pg ex inhalator, 900 pg til 2400 pg ex inhalator, 900 pg til 2700 pg ex inhalator, fortrinsvis i en dosis på 900 pg til 2700 pg ex inhalator.
13. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 12 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives med under 20 aktiveringer per dosis, fortrinsvis 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 eller 1 aktivering per dosis, mest foretrukket indgives ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf under anvendelse af 8 eller færre aktiveringer per dosis.
14. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 13 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives i 1 til 3 doser per dag, fortrinsvis 1 til 2 doser per dag.
15. Ciclesonid eller et farmaceutisk acceptabelt salt deraf eller en sammensætning omfattende ciclesonid eller et farmaceutisk acceptabelt salt deraf ifølge krav 1 til 14 til anvendelse i en fremgangsmåde til behandling af en luftvejssygdom hos hovdyr, fortrinsvis heste, hvor ciclesonid eller det farmaceutisk acceptable salt deraf eller sammensætningen omfattende ciclesonid eller det farmaceutisk acceptable salt deraf indgives over et længere tidsrum på mindst 1 uge, mindst 2, 3, 4, 5, 6, 7, 8, 9 eller 10 uger eller længere.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12199302 | 2012-12-21 | ||
| PCT/EP2013/077265 WO2014096115A1 (en) | 2012-12-21 | 2013-12-18 | Ciclesonide for the treatment of airway disease in horses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2934479T3 true DK2934479T3 (da) | 2018-11-05 |
Family
ID=47552829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13811924.3T DK2934479T3 (da) | 2012-12-21 | 2013-12-18 | Ciclesonid til behandling af luftvejssygdomme hos heste |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20140179651A1 (da) |
| EP (1) | EP2934479B1 (da) |
| AR (1) | AR094241A1 (da) |
| AU (2) | AU2013360691B2 (da) |
| BR (2) | BR122016029247A2 (da) |
| CA (1) | CA2888428C (da) |
| CY (2) | CY1121115T1 (da) |
| DK (1) | DK2934479T3 (da) |
| ES (1) | ES2693779T3 (da) |
| FR (1) | FR20C1026I1 (da) |
| HR (1) | HRP20181980T1 (da) |
| HU (1) | HUS2000020I1 (da) |
| IN (1) | IN2015DN02894A (da) |
| LT (2) | LT2934479T (da) |
| MA (1) | MA38169B2 (da) |
| MX (1) | MX368306B (da) |
| NO (1) | NO2020014I1 (da) |
| NZ (1) | NZ706573A (da) |
| PL (1) | PL2934479T3 (da) |
| PT (1) | PT2934479T (da) |
| RS (1) | RS57740B1 (da) |
| SI (1) | SI2934479T1 (da) |
| WO (1) | WO2014096115A1 (da) |
| ZA (1) | ZA201502288B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089645A1 (es) | 2011-08-12 | 2014-09-10 | Boehringer Ingelheim Vetmed | Particula multicapas de sabor enmascarado, metodo, uso, composicion farmaceutica |
| HRP20181980T1 (hr) | 2012-12-21 | 2019-01-25 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za liječenje dišnih puteva kod konja |
| US10925964B2 (en) | 2012-12-21 | 2021-02-23 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical formulation comprising ciclesonide |
| MX370430B (es) | 2014-06-18 | 2019-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos. |
| WO2018070819A1 (ko) * | 2016-10-14 | 2018-04-19 | 제주대학교 산학협력단 | 시클레소나이드를 포함하는, 암 줄기세포 성장 억제용 조성물 |
| US20230033224A1 (en) * | 2020-01-10 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonide for ameliorating quality of life (qol) in equines |
| FI4188327T3 (fi) | 2020-07-31 | 2025-07-25 | Chemo Res S L | Yhdistelmähoito inhalaatioannosteluun |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5954049A (en) | 1991-10-15 | 1999-09-21 | Trudell Medical Limited | Equine mask with MDI adapter |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| US5823179A (en) | 1996-02-13 | 1998-10-20 | 1263152 Ontario Inc. | Nebulizer apparatus and method |
| US6264923B1 (en) * | 1998-05-13 | 2001-07-24 | 3M Innovative Properties Company | Medicinal aerosol formulation of ciclesonide and related compounds |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
| DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
| US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| WO2004023984A2 (en) | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| US20060293293A1 (en) | 2003-05-22 | 2006-12-28 | Altana Pharma Ag | Salmeterol and ciclesonide combination |
| US20050020692A1 (en) | 2003-07-24 | 2005-01-27 | Ciofalo Vincent B. | Treatment of heaves |
| AU2004271744B2 (en) | 2003-09-16 | 2010-07-29 | Covis Pharma B.V. | Use of ciclesonide for the treatment of respiratory diseases |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| EP1740188A1 (en) | 2004-04-20 | 2007-01-10 | Altana Pharma AG | Use of ciclesonide for the treatment of respiratory diseases in a smoking patient |
| CA2568834A1 (en) | 2004-06-29 | 2006-01-12 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising steroids and an anticholinergic |
| DE102004056579A1 (de) | 2004-11-23 | 2006-05-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum, Salmeterol und ein Steroid |
| UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| UY30542A1 (es) | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| CN102458541A (zh) | 2009-06-25 | 2012-05-16 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 吸入器 |
| US7829748B1 (en) * | 2009-09-21 | 2010-11-09 | Honeywell International Inc. | Process for the manufacture of 1,3,3,3-tetrafluoropropene |
| EA201590030A1 (ru) | 2012-07-05 | 2015-09-30 | Арвен Айлак Санайи Ве Тиджарет А.С. | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент |
| WO2014007766A1 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| US9539408B2 (en) | 2012-10-31 | 2017-01-10 | Trudell Medical International | Nebulizer apparatus |
| HRP20181980T1 (hr) | 2012-12-21 | 2019-01-25 | Boehringer Ingelheim Vetmedica Gmbh | Ciklezonid za liječenje dišnih puteva kod konja |
| US10925964B2 (en) | 2012-12-21 | 2021-02-23 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical formulation comprising ciclesonide |
| HRP20201987T1 (hr) | 2013-08-20 | 2021-02-05 | Boehringer Ingelheim Vetmedica Gmbh | Inhalator |
| EP3035885B1 (en) | 2013-08-20 | 2019-12-25 | Boehringer Ingelheim Vetmedica GmbH | Inhaler |
| MX370430B (es) | 2014-06-18 | 2019-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistas muscarínicos y sus combinaciones para el tratamiento de enfermedades de las vías respiratorias en caballos. |
-
2013
- 2013-12-18 HR HRP20181980TT patent/HRP20181980T1/hr unknown
- 2013-12-18 CA CA2888428A patent/CA2888428C/en active Active
- 2013-12-18 NZ NZ70657313A patent/NZ706573A/en unknown
- 2013-12-18 WO PCT/EP2013/077265 patent/WO2014096115A1/en not_active Ceased
- 2013-12-18 DK DK13811924.3T patent/DK2934479T3/da active
- 2013-12-18 EP EP13811924.3A patent/EP2934479B1/en active Active
- 2013-12-18 AU AU2013360691A patent/AU2013360691B2/en active Active
- 2013-12-18 BR BR122016029247-9A patent/BR122016029247A2/pt not_active Application Discontinuation
- 2013-12-18 SI SI201331266T patent/SI2934479T1/sl unknown
- 2013-12-18 RS RS20181190A patent/RS57740B1/sr unknown
- 2013-12-18 MA MA38169A patent/MA38169B2/fr unknown
- 2013-12-18 MX MX2015007947A patent/MX368306B/es active IP Right Grant
- 2013-12-18 ES ES13811924.3T patent/ES2693779T3/es active Active
- 2013-12-18 US US14/132,580 patent/US20140179651A1/en not_active Abandoned
- 2013-12-18 PT PT13811924T patent/PT2934479T/pt unknown
- 2013-12-18 IN IN2894DEN2015 patent/IN2015DN02894A/en unknown
- 2013-12-18 PL PL13811924T patent/PL2934479T3/pl unknown
- 2013-12-18 US US14/654,009 patent/US9918995B2/en active Active
- 2013-12-18 BR BR112015010842-3A patent/BR112015010842B1/pt active IP Right Grant
- 2013-12-18 LT LTEP13811924.3T patent/LT2934479T/lt unknown
- 2013-12-20 AR ARP130104978A patent/AR094241A1/es not_active Application Discontinuation
-
2015
- 2015-04-07 ZA ZA2015/02288A patent/ZA201502288B/en unknown
-
2016
- 2016-10-13 US US15/292,765 patent/US10258634B2/en active Active
-
2018
- 2018-02-06 US US15/889,307 patent/US10441597B2/en active Active
- 2018-03-07 AU AU2018201642A patent/AU2018201642B2/en active Active
- 2018-11-09 CY CY181101189T patent/CY1121115T1/el unknown
-
2020
- 2020-06-12 NO NO2020014C patent/NO2020014I1/no unknown
- 2020-06-18 LT LTPA2020511C patent/LTPA2020511I1/lt unknown
- 2020-06-26 FR FR20C1026C patent/FR20C1026I1/fr active Active
- 2020-06-29 CY CY2020015C patent/CY2020015I2/el unknown
- 2020-06-29 HU HUS2000020C patent/HUS2000020I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201642B2 (en) | Ciclesonide for the treatment of airway disease in horses | |
| US10682345B2 (en) | Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses | |
| EP3473255B1 (en) | Pharmaceutical formulation comprising ciclesonide | |
| US20230033224A1 (en) | Ciclesonide for ameliorating quality of life (qol) in equines |